Kitazato Q1 Sales Climb 24% on 32% Overseas Growth as Operating Margin Holds Above 50%

Kitazato Corporation (TSE: 368A) reported consolidated results for the first quarter of the fiscal year ending March 2027 — the three months from April 1 to June 30, 2026 — under Japanese GAAP. Net sales rose 24.0% to ¥3,017 million from ¥2,434 million, operating profit 27.0% to ¥1,517 million from ¥1,195 million, ordinary profit 36.5% to ¥1,535 million from ¥1,125 million and profit attributable to owners of the parent 35.1% to ¥1,007 million from ¥745 million. Basic earnings per share were ¥25.18 against ¥18.64; no diluted figure is presented. Comprehensive income of ¥1,007 million matched net profit exactly, the group having recorded no other comprehensive income in the period. The company supplies the assisted-reproduction market — culture media, cryopreservation devices for eggs and embryos, medical devices and micro tools — and reports as a single medical-device segment, so no segment table is disclosed.

Overseas markets supplied two-thirds of sales and almost all of the growth

Kitazato attributes the demand backdrop to later marriage and later childbearing, together with rising social recognition of fertility treatment, in Japan and abroad alike. Domestically it points to a widening network of institutions providing assisted reproductive care and to the build-out of public support such as subsidies for egg freezing; overseas it expects the fertility-treatment market to keep expanding over the medium to long term as support schemes and care-delivery systems improve. Overseas sales rose 31.6% to ¥2,024 million and accounted for 67.1% of the total, while Japan rose 10.9% to ¥993 million — a domestic figure the company says was helped not only by firm underlying demand but by temporary orders placed on concerns about the situation in the Middle East. Within the overseas total, Europe rose 34.5% to ¥1,135 million, the United States 30.8% to ¥317 million, India 6.2% to ¥154 million and other regions 67.9% to ¥290 million. China was the single decline, slipping 5.0% to ¥126 million.

All five product categories grew, led by a 44% rise in Cryodevice

Every product line finished ahead of the prior-year quarter. Media, the largest category, rose 16.0% to ¥1,071 million, and medical devices rose 16.5% to ¥707 million; the company credits new products launched in the previous year with driving the expansion in both. Cryodevice — the vitrification hardware used to freeze eggs and embryos — was the fastest grower, up 43.7% to ¥810 million on steady demand both in Japan and overseas, and now represents 26.8% of sales against 23.1% a year earlier. Micro Tools rose 28.0% to ¥362 million on demand centred on Europe and the United States, and other products rose 17.4% to ¥66 million. During the quarter the group worked on strengthening its overseas business base, introducing new and improved products, accumulating intellectual property and building out production and supply capacity.

A 50% operating margin resting on a 62.5% gross margin and lower overheads

The unusually high operating margin is a function of two lines. Gross profit rose 20.2% to ¥1,886 million — slower than the 24.0% sales increase, because a change in product mix pushed the cost-of-sales ratio up and trimmed the gross margin to 62.5% from 64.4%. Against that, selling, general and administrative expenses fell, to ¥368 million from ¥373 million, so that overheads absorbed only 12.2% of sales against 15.3% a year earlier. Operating profit therefore grew faster than either sales or gross profit, at 27.0%, and the operating margin widened to 50.3% from 49.1%. Depreciation, including amortisation of intangibles, was ¥52 million against ¥43 million.

Ordinary profit outgrew operating profit as listing costs disappeared

Ordinary profit advanced 36.5%, a full nine points faster than operating profit, for two reasons the company sets out explicitly. Non-operating income of ¥18 million — against ¥1 million a year earlier — included ¥13 million of foreign-exchange gains and ¥5 million of interest income. More significantly, non-operating expenses fell to effectively nil from ¥70 million, of which ¥49 million had been listing-related expenses and ¥20 million foreign-exchange losses in the year-earlier quarter. With no extraordinary items on either side in either period, pre-tax profit equalled ordinary profit at ¥1,535 million; income taxes of ¥528 million net left profit attributable to owners of the parent at ¥1,007 million, a net margin of 33.4%. Tax expense for the quarter is computed under the permitted interim method, applying a reasonably estimated effective rate for the full year to pre-tax quarterly profit.

Net assets fell despite the profit, because ¥1,640 million of dividends were paid

Total assets ended the quarter at ¥20,995 million, down ¥1,001 million from the March year-end, principally because cash and deposits fell ¥902 million to ¥12,512 million. Total liabilities fell ¥368 million to ¥1,123 million, mainly on a ¥423 million reduction in income taxes payable to ¥535 million. Net assets fell ¥632 million to ¥19,871 million — a decline in a profitable quarter, which the company explains directly: the ¥1,007 million of quarterly profit was outweighed by ¥1,640 million of dividends paid, the year-end distribution on the year to March 2026 settled during the period. Because liabilities are so small relative to the balance sheet, the equity ratio rose to 94.6% from 93.2%; stated capital is just ¥10 million against retained earnings of ¥19,861 million. No quarterly consolidated cash-flow statement was prepared for the period, and there were no items to report on material changes in shareholders' equity or on going-concern assumptions.

Full-year guidance and the ¥41.00 dividend forecast both left unchanged

Kitazato repeated the full-year plan it published on April 30, 2026, stating that there is no revision. For the year to March 2027 it guides net sales of ¥11,346 million, up 3.6%, operating profit of ¥6,115 million, up 4.4%, ordinary profit of ¥6,137 million, up 4.0%, and profit attributable to owners of the parent of ¥4,059 million, up 4.2%, for earnings per share of ¥101.50. The first quarter therefore covers 26.6% of the sales target and 24.8% of both the operating- and net-profit targets. The dividend plan is likewise unrevised: the company paid ¥41.00 for the year to March 2026 — nothing at the half-year and ¥41.00 at the year-end — and forecasts the same year-end-only ¥41.00 for the year to March 2027, with ¥0.00 at the second-quarter end. On 40,000,000 shares outstanding, that is the ¥1,640 million distribution reflected in the balance sheet above.

Name shortened to 株式会社北里 on July 1 as a new mid-term plan begins

Two corporate developments frame the quarter. In June 2026 the company published a mid-term management plan positioned as the first stage of a long-term vision it calls "Kitazato Challenge 2036", aimed at sustaining growth in the existing business while building the foundations for future growth. Then, on July 1, 2026 — the day after the quarter closed — it shortened its Japanese trade name from 株式会社北里コーポレーション to 株式会社北里, saying it will operate under the new name in pursuit of its corporate philosophy, "Happiness, for the Next Generations." There was no material change to the scope of consolidation and no change of accounting policy, estimate or restatement during the quarter. Shares outstanding were unchanged at 40,000,000, and the weighted-average count used for earnings per share was the same 40,000,000 in both periods. The quarterly consolidated financial statements were subject to a voluntary interim review by the company's independent auditor, which reported no matters requiring modification.

JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.